Document is current
Any future updates will be listed below
-
Authors
Ojanen, Markus JT
Seiskari, Tapio
Aittoniemi, Janne
Huhtala, Heini
Huttunen, Reetta
Syrjänen, Jaana
Junttila, Ilkka
Pesu, Marko
Rannikko, Juha https://orcid.org/0000-0002-7199-6306
-
Funding
Funding for this research was provided by:
Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital / Fimlab Laboratories / NordLab (X50060, 9N075, X51409, X50070)
Tampereen Tuberkuloosisäätiö
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 27 October 2025
First Online: 26 November 2025
Declarations
:
: The authors declare no competing interests.
: Markus Ojanen: No conflicts of interest,Tapio Seiskari: No conflicts of interest,Janne Aittoniemi: A member of the Nordic Infucare AB Finnish advisory board,Heini Huhtala: No conflicts of interest,Reetta Huttunen: No conflicts of interest,Jaana Syrjänen: No conflicts of interest, Ilkka Junttila: No conflicts of interest,Marko Pesu: No conflicts of interest,Juha Rannikko: International congress attendance fee from Gilead and Pfizer.
